Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 6/2009

01-05-2009 | Short Communication

Isolated molecular relapse in FIP1L1-PDGFRα hypereosinophilic syndrome after discontinuation and single weekly dose of imatinib: need of quantitative molecular procedures to modulate imatinib dose

Authors: Massimo Breccia, Daniela Cilloni, Laura Cannella, Caterina Stefanizzi, Agostino Tafuri, Angelo Fama, Michelina Santopietro, Giuseppe Saglio, Giuliana Alimena

Published in: Cancer Chemotherapy and Pharmacology | Issue 6/2009

Login to get access

Abstract

Imatinib is the treatment of choice for FIP1L1-PDGFRα (F/P+) positive myeloproliferative neoplasms, but little is known about optimal dose and duration of treatment to maintain complete molecular remission once achieved. We describe a case of F/P+ patients who started imatinib and reached a molecular remission, but did relapse after 15 months of therapy for poor adherence to therapy, and re-obtained remission only with standard dose of 400 mg/day. We reviewed the literature and highlights the need of quantitative molecular procedures to modulate imatinib dose.
Literature
1.
Chusid MJ, Dale DC, West BC, Wolff SM (1975) The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine 54:1–27PubMedCrossRef
2.
Gotlib J, Cools J, Malone JM, Schrier SL, Gilliland DG, Coutre SE (2004) The FIP1L1-PDGFRa fusion tyrosine kinase in hyper eosinophilic syndrome and chronic eosinophilic leukaemia: implications for diagnosis, classification and management. Blood 103:2879–2891PubMedCrossRef
3.
Klion AD, Robyn J, Akin C, Noel P, Brown M, Law M, Metcalfe DD, Dunbar C, Nutman TB (2004) Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. Blood 103:473–478PubMedCrossRef
4.
Schaller JL, Burkland GA (2001) Case report: rapid and complete control of idiopathic hypereosinophilia with imatinib mesylate. Med Gen Med 3:9
5.
Baccarani M, Cilloni D, Rondoni M, Ottaviani E, Messa F, Merante S, Tiribelli M, Buccisano F, Testoni N, Gottardi E, De Vivo A, Giugliano E, Iacobucci I, Paolini S, Soverini S, Rosti G, Rancati F, Astolfi C, Pane F, Saglio G, Martinelli G (2007) The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRa positive hypereosinophilic syndrome. Results of a multicenter prospective study. Haematologica 92:1173–1179PubMedCrossRef
6.
Helbig G, Stella-Holowiecka B, Grosicki S, Bober G, Krawczyk M, Wojnar J, Reiter A, Hochhaus A, Holowiecki J (2006) The results of imatinib therapy for patients with primary eosinophilic disorders. Eur J Haematol 76:535–536PubMedCrossRef
7.
Cilloni D, Messa F, Martinelli G, Gottardi E, Arruga F, Defilippi I, Carturan S, Messa E, Fava M, Giugliano E, Rosso V, Catalano R, Merante S, Nicoli P, Rondomi M, Ottaviani E, Soverini S, Tiribelli M, Pane F, Baccarani M, Saglio G (2007) WT1 transcript amount discriminates secondary or reactive eosinophilia from idiopathic hypereosinophilic syndrome or chronic eosinophilic leukaemia. Leukemia 21:1442–1450PubMedCrossRef
8.
Tefferi A, Vardiman JW (2008) Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 22:14–22PubMedCrossRef
9.
Cools J, De Angelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, Kutok J, Clark J, Galinsky I, Griffin JD, Cross NC, Tefferi A, Malone J, Alam R, Schrier SL, Schmid J, Rose M, Vandenberghe P, Verhoef G, Boogaerts M, Wlodarska I, Kantarjian H, Marynen P, Coutre SE, Stone R, Gilliland DG (2003) A tyrosine kinase created by fusion of the PDGFRa and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. New Engl J Med 348:1201–1214PubMedCrossRef
10.
Pardanani A, Ketterling RP, Li CY, Patnaik MM, Wolanskyi AP, Elliott MA, Camoriano JK, Butterfield JH, Dewald GW, Tefferi A (2006) FIP1L1-PDGFRa in eosinophilic disorders: prevalence in routine clinical practice, long term experience with imatinib therapy and a critical review of the literature. Leuk Res 30:965–970PubMedCrossRef
11.
Tefferi A, Patnaik MM, Pardanani A (2006) Eosinophilia: secondary, clonal and idiopathic. Br J Haematol 133:468–492PubMedCrossRef
12.
Klion AD, Robyn J, Maric I, Fu W, Schmid I, Lemery S, Noel P, Law MA, Hatsell M, Talar-Williams C, Fay MP, Dunbar CE, Nutman TB (2007) Relapse following discontinuation of imatinib mesylate therapy for FIP1L1-PDGFRa-positive chronic eosinophilic leukaemia: implications for optimal dosing. Blood 110:3352–3356CrossRef
13.
Helbig G, Holowiecka SB, Majewski M, Calbecka M, Gajkowska G, Klimkiewicz R, Moskwa A, Grzegorczyk J, Lewandowska M, Holowiecki J (2008) A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukaemia in FIP1L1-PDGFRa-expressing patients. Br J Haematol 141:200–204PubMedCrossRef
Metadata
Title
Isolated molecular relapse in FIP1L1-PDGFRα hypereosinophilic syndrome after discontinuation and single weekly dose of imatinib: need of quantitative molecular procedures to modulate imatinib dose
Authors
Massimo Breccia
Daniela Cilloni
Laura Cannella
Caterina Stefanizzi
Agostino Tafuri
Angelo Fama
Michelina Santopietro
Giuseppe Saglio
Giuliana Alimena
Publication date
01-05-2009
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 6/2009
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-008-0858-8

Other articles of this Issue 6/2009

Cancer Chemotherapy and Pharmacology 6/2009 Go to the issue

Short Communication

Extended survival of a HER-2-positive metastatic breast cancer patient with brain metastases also treated with intrathecal trastuzumab

Original Article

Phase I and pharmacokinetic study of mitomycin C and celecoxib as potential modulators of tumor resistance to irinotecan in patients with solid malignancies

Original Article

Statins induce apoptosis in ovarian cancer cells through activation of JNK and enhancement of Bim expression

Original Article

Mechanistic population pharmacokinetics of total and unbound paclitaxel for a new nanodroplet formulation versus Taxol in cancer patients

Original Article

Irinotecan monotherapy as second-line treatment in advanced pancreatic cancer

Original Article

Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits